The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001
- PMID: 23398354
- PMCID: PMC3875218
- DOI: 10.1667/RR2892.1
The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001
Abstract
A marked increase in leukemia risks was the first and most striking late effect of radiation exposure seen among the Hiroshima and Nagasaki atomic bomb survivors. This article presents analyses of radiation effects on leukemia, lymphoma and multiple myeloma incidence in the Life Span Study cohort of atomic bomb survivors updated 14 years since the last comprehensive report on these malignancies. These analyses make use of tumor- and leukemia-registry based incidence data on 113,011 cohort members with 3.6 million person-years of follow-up from late 1950 through the end of 2001. In addition to a detailed analysis of the excess risk for all leukemias other than chronic lymphocytic leukemia or adult T-cell leukemia (neither of which appear to be radiation-related), we present results for the major hematopoietic malignancy types: acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, adult T-cell leukemia, Hodgkin and non-Hodgkin lymphoma and multiple myeloma. Poisson regression methods were used to characterize the shape of the radiation dose-response relationship and, to the extent the data allowed, to investigate variation in the excess risks with gender, attained age, exposure age and time since exposure. In contrast to the previous report that focused on describing excess absolute rates, we considered both excess absolute rate (EAR) and excess relative risk (ERR) models and found that ERR models can often provide equivalent and sometimes more parsimonious descriptions of the excess risk than EAR models. The leukemia results indicated that there was a nonlinear dose response for leukemias other than chronic lymphocytic leukemia or adult T-cell leukemia, which varied markedly with time and age at exposure, with much of the evidence for this nonlinearity arising from the acute myeloid leukemia risks. Although the leukemia excess risks generally declined with attained age or time since exposure, there was evidence that the radiation-associated excess leukemia risks, especially for acute myeloid leukemia, had persisted throughout the follow-up period out to 55 years after the bombings. As in earlier analyses, there was a weak suggestion of a radiation dose response for non-Hodgkin lymphoma among men, with no indication of such an effect among women. There was no evidence of radiation-associated excess risks for either Hodgkin lymphoma or multiple myeloma.
Figures
Similar articles
-
Solid Cancer Incidence among the Life Span Study of Atomic Bomb Survivors: 1958-2009.Radiat Res. 2017 May;187(5):513-537. doi: 10.1667/RR14492.1. Epub 2017 Mar 20. Radiat Res. 2017. PMID: 28319463 Free PMC article.
-
Cancer and non-cancer effects in Japanese atomic bomb survivors.J Radiol Prot. 2009 Jun;29(2A):A43-59. doi: 10.1088/0952-4746/29/2A/S04. Epub 2009 May 19. J Radiol Prot. 2009. PMID: 19454804 Review.
-
Solid cancer incidence in atomic bomb survivors: 1958-1998.Radiat Res. 2007 Jul;168(1):1-64. doi: 10.1667/RR0763.1. Radiat Res. 2007. PMID: 17722996
-
Dose response and temporal patterns of radiation-associated solid cancer risks.Health Phys. 2003 Jul;85(1):43-6. doi: 10.1097/00004032-200307000-00010. Health Phys. 2003. PMID: 12852470 Review.
-
Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987.Radiat Res. 1994 Feb;137(2 Suppl):S68-97. Radiat Res. 1994. PMID: 8127953
Cited by
-
miR-4716-3p and the target AKT2 Gene/rs2304186 SNP are associated with blood cancer pathogenesis in Pakistani population.Noncoding RNA Res. 2024 Mar 14;9(3):695-703. doi: 10.1016/j.ncrna.2024.03.005. eCollection 2024 Sep. Noncoding RNA Res. 2024. PMID: 38577021 Free PMC article.
-
A generalisation of the method of regression calibration and comparison with Bayesian and frequentist model averaging methods.Sci Rep. 2024 Mar 19;14(1):6613. doi: 10.1038/s41598-024-56967-6. Sci Rep. 2024. PMID: 38503853 Free PMC article.
-
A generalisation of the method of regression calibration and comparison with Bayesian and frequentist model averaging methods.ArXiv [Preprint]. 2024 Mar 13:arXiv:2312.02215v3. ArXiv. 2024. Update in: Sci Rep. 2024 Mar 19;14(1):6613. doi: 10.1038/s41598-024-56967-6. PMID: 38196750 Free PMC article. Updated. Preprint.
-
A generalisation of the method of regression calibration and comparison with the Bayesian 2-dimensional Monte Carlo method.Res Sq [Preprint]. 2023 Dec 5:rs.3.rs-3700052. doi: 10.21203/rs.3.rs-3700052/v1. Res Sq. 2023. PMID: 38106092 Free PMC article. Preprint.
-
Therapy-Related Myeloid Neoplasms: Predisposition and Clonal Evolution.Mediterr J Hematol Infect Dis. 2023 Nov 1;15(1):e2023064. doi: 10.4084/MJHID.2023.064. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 38028397 Free PMC article. Review.
References
-
- Dunlap CE. Effects of radiation on normal cells. III. Effects of radiation on the blood and the hematopoietic tisues, including the spleen, the thymus, and the lymph nodes. Arch Path. 1942;3:562–608.
-
- Henshaw PS, Hawkins JW. Incidence of leukemia in physicians. J Natl Cancer Inst. 1944;4:339–46.
-
- Folley JH, Borges W, Yamasaki T. Incidence of leukemia in survivors of the atomic bomb in Hiroshima and Nagasaki, Japan. American Journal of Medicine. 1952;13:311–21. - PubMed
-
- Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res. 1994;137(2 Suppl):S68–S97. - PubMed
-
- Pierce DA, Shimizu Y, Preston DL, Vaeth M, Mabuchi K. Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950–1990. Radiat Res. 1996;146(1):1–27. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials